Aspirin and Proton Pump Inhibitor Combination Therapy for Prevention of Cardiovascular Disease and Barrett's Esophagus

References

• . Baigent C, Sudlow C, Collins R, Peto R. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
   PubMedGoogle Scholar
• . Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41
   PubMed Web of Science ®Google Scholar
• . Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012;26(2):125–140
   PubMed Web of Science ®Google Scholar
• . , American Gastroenterological AssociationWilcox CM, Allison J, Benzuly K, . Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol. 2006;4(9):1082–1089
   PubMedGoogle Scholar
• . Peura DA, Lanza FL, Gostout CJ, Foutch PG. The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol. 1997;92(6):924–928
   PubMed Web of Science ®Google Scholar
• . Yeomans ND, Lanas AI, Talley NJ, . Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22(9):795–801
   PubMed Web of Science ®Google Scholar
• . Scheiman JM. Prevention of damage induced by aspirin in the GI tract. Best Pract Res Clin Gastroenterol. 2012;26(2):153–162
   PubMed Web of Science ®Google Scholar
• . Bhatt DL, Cryer BL, Contant CF, ; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–1917
   PubMed Web of Science ®Google Scholar
• . Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther. 2000;14(5):529–534
   PubMedGoogle Scholar
• . Lai KC, Lam SK, Chu KM, . Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033–2038
   PubMed Web of Science ®Google Scholar
• . Ng FH, Wong SY, Lam KF, . Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138(1):82–88
   PubMed Web of Science ®Google Scholar
• . Scheiman JM, Devereaux PJ, Herlitz J, . Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97(10):797–802
   PubMed Web of Science ®Google Scholar
• . Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9684):119–125
   PubMed Web of Science ®Google Scholar
• . Yeomans N, Lanas A, Labenz J, . Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103(10):2465–2473
   PubMed Web of Science ®Google Scholar
• . Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719
   PubMed Web of Science ®Google Scholar
• . Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr Hypertens Rep. 2007;9(3):184–189
   PubMed Web of Science ®Google Scholar
• . Hoyert DL. 75 years of mortality in the United States, 1935–2010. NCHS Data Brief. 2012(88):1–8
   Google Scholar
• . Hunt RH, Yuan Y. Acid-NSAID/aspirin interaction in peptic ulcer disease. Dig Dis. 2011;29(5):465–468
   PubMedGoogle Scholar
• . Smith SC, Benjamin EJ, Bonow RO, ; World Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22);2458–2473
   PubMed Web of Science ®Google Scholar
• . Pearson TA, Blair SN, Daniels SR, . AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388–391
   PubMed Web of Science ®Google Scholar
• . Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308(6923):235–246
   PubMed Web of Science ®Google Scholar
• . Levine DM, Bates DW, Blankenship JC, . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574–e651
   PubMed Web of Science ®Google Scholar
• . Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011;123(7):768–778
   PubMed Web of Science ®Google Scholar
• . Dai Y, Ge J. Clinical use of aspirin in treatment and prevention of cardiovascular disease. Thrombosis. 2012;2012:245037
   PubMedGoogle Scholar
• . Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–235
   PubMedGoogle Scholar
• . Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke. 1990;21( 12 Suppl):IV12–IV23
   PubMedGoogle Scholar
• . Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers PRev. 2010; 19(6):1468–1470
   PubMed Web of Science ®Google Scholar
• . Fortuny J, Johnson CC, Bohlke K, . Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol. 2007;5(10):1154–1159e3
   PubMedGoogle Scholar
• . Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009;7(12):1299–1304
   PubMed Web of Science ®Google Scholar
• . Bosetti C, Rosato V, Gallus S, Cusick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403–1415
   PubMed Web of Science ®Google Scholar
• . Cole BF, Logan RF, Halabi S, . Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256–266
   PubMedGoogle Scholar
• . Buttar NS, Wang KK. The “aspirin” of the new millennium: cyclooxygenase-2 inhibitors. Mayo Clin Proc. 2000;75(10):1027–1038
   PubMedGoogle Scholar
• . Falk GW, Buttar NS, Foster NR, ; Canver Prevention Network. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology. 2012;143(4):917–926e1
   PubMedGoogle Scholar
• . Kostadinov RL, Kuhner MK, Li X, . NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet. 2013;9(6):e1003553
   PubMedGoogle Scholar
• . Fendrick AM, Scheiman JM. Helicobacter pylori and NSAID gastropathy: an ambiguous association. Curr Rheumatol Rep. 2001;3(2):107–111
   PubMedGoogle Scholar
• . Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991;32(1):77–83
   PubMed Web of Science ®Google Scholar
• . Hawkey CJ. Review article: aspirin and gastrointestinal bleeding. Aliment Pharmacol Ther. 1994;8(2):141–146
   PubMed Web of Science ®Google Scholar
• . Tamura A, Murakami K, Kadota J, . Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. QJM. 2011;104(2):133–139
   PubMed Web of Science ®Google Scholar
• . Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol. 2001;61(6):631–637
   PubMed Web of Science ®Google Scholar
• . Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272–277
   PubMed Web of Science ®Google Scholar
• . Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol. 2005;32(11):2218–2224
   PubMed Web of Science ®Google Scholar
• . Sorensen HT, Mellemkjaer L, Blot WJ, . Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95(9):2218–2224
   PubMed Web of Science ®Google Scholar
• . Abraham NS, Hlatky MA, Antman EM, ; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2010;122:2619–2633
   PubMed Web of Science ®Google Scholar
• . Silverstein FE, Graham DY, Senior JR, . Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241–249
   PubMed Web of Science ®Google Scholar
• . Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010;32(4):667–677
   PubMedGoogle Scholar
• . Wurtz M, Grove EL. Combining aspirin and proton pump inhibitors: for whom the warning bell tolls? Expert Opin Drug Metab Toxicol. 2012;8(9):1051–1055
   PubMed Web of Science ®Google Scholar
• . Cullen D, Bardhan KD, Eisner M, . Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998;12(2):135–140
   PubMed Web of Science ®Google Scholar
• . Graham DY, Agrawal NM, Campbell DR, ; NSAIS-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162(2):169–175
   PubMed Web of Science ®Google Scholar
• . Yeomans ND, Tulassay Z, Juhasz L, . A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338(11):719–726
   PubMed Web of Science ®Google Scholar
• . Scheiman JM, Yeomans ND, Talley NJ, . Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101(4):701–710
   PubMed Web of Science ®Google Scholar
• . Chan FK, Chung SC, Suen BY, . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344(13):967–973
   PubMed Web of Science ®Google Scholar
• . Recommendations of Aspirin for Prevention of Cardiovascular Disease. http://www.cdc.gov/heartdisease/aspirin.htm. Published 2011. Accessed November 13, 2013
   Google Scholar
• . Burness CB, Scott LJ. Acetylsalicylic acid/esomeprazole fixed-dose combination. Drugs Aging. 2012;29(3):233–242
   PubMedGoogle Scholar
• . Shmulevich E, Friger M, Gilutz H, Azab AN. Clopidogrel and proton pump inhibitors: is there a significant drug-drug interaction? Can J Cardiovasc Nurs. 2011;21(4):27–36
   PubMedGoogle Scholar
• . Goldstein JL, Chan FK, Lanas A, . Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials. Aliment Pharmacol Ther. 2011;34(7):808–816
   PubMed Web of Science ®Google Scholar
• . Niazi M, Andersson T, Naucler E, Næsdal J. Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg and the monotherapies given separately in healthy volunteers. Int J Clin Pharmacol Ther. 2011;49(2):169–176
   PubMed Web of Science ®Google Scholar
• . Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–1919
   PubMed Web of Science ®Google Scholar
• . Niv Y, Battler A, Abuksis G, . Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci. 2005;50(1):78–80
   PubMed Web of Science ®Google Scholar
• . Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011;171(3):218–225
   PubMedGoogle Scholar
• . Saini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med. 2008;168(15):1684–1690; discussion 16991
   PubMedGoogle Scholar
• . Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology. 2002;122(1):78–84
   PubMedGoogle Scholar
• . Zhu LL, Xu LC, Chen Y, Zhou Q, Zeng S. Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications. World J Gastroenterol. 2012;18(24):3167–3172
   PubMedGoogle Scholar
• . de Jong HJ, Korevaar JC, van Dijk L, Voogd E, van Dijk CE, van Oijen MG. Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care. BMJ Open. 2013;3(7):pii e003044
   Google Scholar
• . El-Serag HB, Aguirre TV, Davis S, . Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004;99(10):1877–1883
   PubMedGoogle Scholar
• . Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust. 2004;180(8):387–391
   PubMed Web of Science ®Google Scholar
• . Kastelein F, Spaander MC, Steyerberg EW, ; ProBar Study Group. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2013;11(4):382–388
   PubMed Web of Science ®Google Scholar
• . Jankowski J, Hunt R. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. Cancer Epidemiol Biomarkers PRev. 2008;17(8):1858–1861
   PubMedGoogle Scholar
• . Smith K. Barrett oesophagus: PPIs might reduce risk of neoplastic progression in Barrett oesophagus. Nat Rev Gastroenterol Hepatol. 2013;10(2):66
   PubMedGoogle Scholar
• . Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11–12):1269–1281
   PubMed Web of Science ®Google Scholar
• . Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–1019
   PubMed Web of Science ®Google Scholar
• . Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–2056; quiz 2057
   PubMed Web of Science ®Google Scholar
• . FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Secondary FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Washinton, DC: US Dept of Health and Human Services; 2012. http://www.fda.gov/drugs/drugsafety/ucm290510.htm. Accessed November 14, 2013
   Google Scholar
• . Tleyjeh IM, Bin Abdulhak AA, Riaz M, . Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012;7(12):e50836
   PubMed Web of Science ®Google Scholar
• . FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Washinton, DC: US Dept of Health and Human Services; 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm#SafetyAnnouncement. Accessed November 14, 2013
   Google Scholar
• . FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Washinton, DC: US Dept of Health and Human Services; 2011. http://www.fda.gov/drugs/drugsafety/ucm245011.htm. Accessed November 12, 2013
   Google Scholar
• . Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Published 2009. Accessed November 13, 2013
   Google Scholar
• . Charlot M, Grove EL, Hansen PR, . Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690
   PubMed Web of Science ®Google Scholar
• . Newby LK, LaPointe NM, Chen AY, . Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–112
   PubMed Web of Science ®Google Scholar
• . Ziegelstein R. Adherence to medication regimens and recommended lifestyle changes in patients with cardiovascular disease. Adv Stud Med. 2003;3:150–156
   Google Scholar
• . Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310
   PubMed Web of Science ®Google Scholar
• . Schiff M, Peura D. HZT-501 (DUEXIS((R)); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol. 2012;6(1):25–35
   PubMed Web of Science ®Google Scholar
• . Heads of Medicines Agencies. Summary of Product Characteristics and Package Leaflet for Axanum. Wedel, Germany: Astra Zeneca GmbH; 2011. http://mri.medagencies.org/download/DE_H_2749_001_FinalPI.pdf
   Google Scholar
• . UK Medicines Information. New Drugs Online. New Drugs Online Report for esomeprazole + aspirin. http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5096. Accessed October 30, 2013
   Google Scholar
• . Health MaSU. Ulcer aspirin combo drug, Axanum, gets EU approval. http://www.stonehearthnewsletters.com/ulcer-aspirin-combo-drug-axanum-gets-eu-approval/updates/. Published 2011. Accessed November 11, 2013
   Google Scholar
• . Axanum And Expanded Nexium Indication Rejected By FDA [press release]. Medical News Today. http://www.medicalnewstoday.com/articles/190523.php. Published June 1, 2010. Accessed October 28, 2013
   Google Scholar
• . Bhatt DL, Scheiman J, Abraham NS, ; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502–1517
   PubMed Web of Science ®Google Scholar
• . Hamm CW, Bassand JP, Agewall S, ; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32(23):2999–3054
   PubMed Web of Science ®Google Scholar